320 related articles for article (PubMed ID: 27567445)
1. The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients.
Yoshioka T; Shigekawa M; Yamai T; Suda T; Kegasawa T; Iwahashi K; Ikezawa K; Sakamori R; Yakushijin T; Hiramatsu N; Tatsumi T; Takehara T
Pancreatology; 2016; 16(6):1020-1027. PubMed ID: 27567445
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy of pancreatic juice cytology for risk classification according to international consensus guidelines in patients with intraductal papillary mucinous neoplasm; a retrospective study.
Yamakawa K; Masuda A; Nakagawa T; Shiomi H; Toyama H; Takenaka M; Sakai A; Kobayashi T; Tsujimae M; Ashina S; Yamada Y; Tanaka T; Tanaka S; Nakano R; Sato Y; Ikegawa T; Kurosawa M; Fujigaki S; Kutsumi H; Itoh T; Fukumoto T; Kodama Y
Pancreatology; 2019 Apr; 19(3):424-428. PubMed ID: 30857854
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
Yamaguchi T; Shirai Y; Ishihara T; Sudo K; Nakagawa A; Ito H; Miyazaki M; Nomura F; Saisho H
Cancer; 2005 Dec; 104(12):2830-6. PubMed ID: 16287152
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic juice cytology as sensitive test for detecting pancreatic malignancy in intraductal papillary mucinous neoplasm of the pancreas without mural nodule.
Kawada N; Uehara H; Nagata S; Tomita Y; Nakamura H
Pancreatology; 2016; 16(5):853-8. PubMed ID: 27459913
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic juice cytology with immunohistochemistry to detect malignancy and histologic subtypes in patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas.
Koshita S; Noda Y; Ito K; Kanno Y; Ogawa T; Masu K; Masaki Y; Horaguchi J; Oikawa M; Tsuchiya T; Sawai T; Uzuki M; Fujishima F
Gastrointest Endosc; 2017 May; 85(5):1036-1046. PubMed ID: 27756613
[TBL] [Abstract][Full Text] [Related]
6. Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012.
Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Ideno N; Aso T; Miyasaka Y; Ueda J; Takahata S; Osoegawa T; Igarashi H; Ito T; Ushijima Y; Ookubo F; Oda Y; Mizumoto K; Tanaka M
World J Surg; 2014 Nov; 38(11):2994-3001. PubMed ID: 25037612
[TBL] [Abstract][Full Text] [Related]
7. Nonprevention of post-endoscopic retrograde cholangiopancreatographic pancreatitis by pancreatic stent after aspiration of pure pancreatic juice in patients with intraductal papillary mucinous neoplasms of the pancreas.
Harada R; Kawamoto H; Fukatsu H; Kato H; Hirao K; Kurihara N; Mizuno O; Ogawa T; Ishida E; Okada H; Yamamoto K; Yamamoto H
Pancreas; 2010 Apr; 39(3):340-4. PubMed ID: 19823100
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.
Kang MJ; Jang JY; Lee S; Park T; Lee SY; Kim SW
World J Surg; 2015 Aug; 39(8):2006-13. PubMed ID: 25894399
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm: systematic review and meta-analysis.
Suzuki R; Thosani N; Annangi S; Komarraju A; Irisawa A; Ohira H; Obara K; Fleming JB; Guha S; Bhutani MS
Dig Endosc; 2014 Jul; 26(4):586-93. PubMed ID: 24450356
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for post-ERCP pancreatitis in high risk patients who have undergone prophylactic pancreatic duct stenting: a multicenter retrospective study.
Ito K; Fujita N; Kanno A; Matsubayashi H; Okaniwa S; Nakahara K; Suzuki K; Enohara R;
Intern Med; 2011; 50(24):2927-32. PubMed ID: 22185981
[TBL] [Abstract][Full Text] [Related]
11. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.
Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
Ann Surg; 2012 Mar; 255(3):517-22. PubMed ID: 22301608
[TBL] [Abstract][Full Text] [Related]
12. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.
Serikawa M; Sasaki T; Fujimoto Y; Kuwahara K; Chayama K
J Clin Gastroenterol; 2006 Oct; 40(9):856-62. PubMed ID: 17016145
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with No change in first 5 Years of diagnosis.
Lee BS; Nguyen AK; Tekeste TF; Chang K; Girgis A; Adeyemo M; Hanna MS; Yao JF; Kwok KK; Giap AQ; Hunt GC; Chaya CT; Kao KT; Attam R; Ko A; Pio JR; Tovar S; Lim BS
Pancreatology; 2021 Jan; 21(1):144-154. PubMed ID: 33309223
[TBL] [Abstract][Full Text] [Related]
14. Peroral pancreatoscopy using the SpyGlass system for the assessment of intraductal papillary mucinous neoplasm of the pancreas.
Nagayoshi Y; Aso T; Ohtsuka T; Kono H; Ideno N; Igarashi H; Takahata S; Oda Y; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):410-7. PubMed ID: 24123930
[TBL] [Abstract][Full Text] [Related]
15. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic juice cytology in IPMN of the pancreas.
Yamaguchi K; Nakamura M; Shirahane K; Kawamoto M; Konomi H; Ohta M; Tanaka M
Pancreatology; 2005; 5(4-5):416-21; discussion 421. PubMed ID: 15985766
[TBL] [Abstract][Full Text] [Related]
17. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
18. Potential predictors of disease progression for main-duct intraductal papillary mucinous neoplasms of the pancreas.
Ogura T; Masuda D; Kurisu Y; Edogawa S; Imoto A; Hayashi M; Uchiyama K; Higuchi K
J Gastroenterol Hepatol; 2013 Nov; 28(11):1782-6. PubMed ID: 23800049
[TBL] [Abstract][Full Text] [Related]
19. Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.
Han Y; Lee H; Kang JS; Kim JR; Kim HS; Lee JM; Lee KB; Kwon W; Kim SW; Jang JY
Gastroenterology; 2018 Feb; 154(3):576-584. PubMed ID: 29074452
[TBL] [Abstract][Full Text] [Related]
20. Thirty years of experience with intraductal papillary mucinous neoplasm of the pancreas: from discovery to international consensus.
Tanaka M
Digestion; 2014; 90(4):265-72. PubMed ID: 25591885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
